No products in the cart.
Pre-made Lodelcizumab benchmark antibody ( Whole mAb, anti-PCSK9 therapeutic antibody, Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-318
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Lodelcizumab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ligelizumab (QGE031) is a humanized monoclonal antibody (mAb) designed for the treatment of severe asthma and chronic spontaneous urticaria. his drug was developed by Novartis Pharma AG. As of 2018, ligelizumab is undergoing Phase III trials. It binds with high affinity to the C¦Å3 domain of IgE.
| Products Name (INN Index) | Pre-Made Lodelcizumab biosimilar, Whole mAb, Anti-PCSK9 Antibody: Anti-FH3/FHCL3/HCHOLA3/LDLCQ1/NARC-1/NARC1/PC9 therapeutic antibody |
|---|---|
| INN Name | Lodelcizumab |
| Target | PCSK9 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Novartis |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Hypercholesterolaemia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | PCSK9 |
| Package |
Previous slide
Next slide
